Therapeutic approaches to genetic ion channelopathies and perspectives in drug discovery

Frontiers in Pharmacology

Volumn 7, Issue MAY, 2016, Pages

  Imbrici, Paola ^a   Liantonio, Antonella ^a   Camerino, Giulia M ^a   De Bellis, Michela ^a   Camerino, Claudia ^a   Mele, Antonietta ^a   Giustino, Arcangela ^a   Pierno, Sabata ^a   De Luca, Annamaria ^a   Tricarico, Domenico ^a   Desaphy, Jean Francois ^a   Conte, Diana ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Channelopathies; Drug discovery and development; Genetics; Ion channels pharmacology; Physiopathology

Indexed keywords

ACETAZOLAMIDE; AJMALINE; AMILORIDE; ANTICONVULSIVE AGENT; BENZTHIAZIDE; CARBAMAZEPINE; DIAZOXIDE; EPLERENONE; FLECAINIDE; ION CHANNEL; MEXILETINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SALBUTAMOL; SOMATOSTATIN DERIVATIVE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOPIRAMATE; TRANSIENT RECEPTOR POTENTIAL CHANNEL;

ALBERS SCHOENBERG DISEASE; BARTTER SYNDROME; BIOPHYSICS; CEREBELLAR ATAXIA; CHANNELOPATHY; DENT DISEASE; DISEASE PREDISPOSITION; DRUG DEVELOPMENT; EPILEPSY; FAMILIAL HEMIPLEGIC MIGRAINE; FRAMESHIFT MUTATION; GABAERGIC TRANSMISSION; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL SYMPTOM; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC TRAIT; GENETIC VARIABILITY; HEART ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERHIDROSIS; HYPERKALEMIA; HYPOKALEMIA; HYPOVOLEMIA; KIDNEY CALCIFICATION; LEUKOENCEPHALOPATHY; MEMBRANE DEPOLARIZATION; MIGRAINE; MISSENSE MUTATION; MOLECULAR DYNAMICS; MUSCLE FATIGUE; MUSCLE RIGIDITY; MYOTONIA; NERVE EXCITABILITY; NEWBORN DIABETES MELLITUS; NONHUMAN; PARESTHESIA; PERIODIC PARALYSIS; PERIPHERAL NERVOUS SYSTEM; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; PHARMACOGENETICS; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; PSYCHOGENIC PAIN; REVIEW; SOCIAL BEHAVIOR; STOICHIOMETRY; STOP CODON; SYNAPTIC TRANSMISSION; THOMSEN DISEASE;

EID: 84974624128     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00121     Document Type: Review

References (285)

1. Alvina, K., and Khodakhah, K. (2010a). KCa channels as therapeutic targets in episodic ataxia type-2. J. Neurosci. 30, 7249-7257. doi: 10.1523/JNEUROSCI.6341-09.2010
2. Alvina, K., and Khodakhah, K. (2010b). The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J. Neurosci. 30, 7258-7268. doi: 10.1523/JNEUROSCI.3582-09.2010
3. Andrini, O., Keck, M., Briones, R., Lourdel, S., Vargas-Poussou, R., and Teulon, J. (2015). ClC-K chloride channels: emerging pathophysiology of Bartter syndrome type 3. Am. J. Physiol. Renal. Physiol. 308, F1324-F1334. doi: 10.1152/ajprenal.00004.2015
4. Arnoux, J. B., Verkarre, V., Saint-Martin, C., Montravers, F., Brassier, A., Valayannopoulos, V., et al. (2011). Congenital hyperinsulinism: current trends in diagnosis and therapy. Orphanet J. Rare Dis. 6, 63. doi: 10.1186/1750-1172-6-63
5. Babenko, A. P., Gonzalez, G., and Bryan, J. (2000). Pharmaco-topology of sulfonylurea receptors. Separate domains of the regulatory subunits of K(ATP) channel isoforms are required for selective interaction with K(+) channel openers. J. Biol. Chem. 275, 717-720. doi: 10.1074/jbc.275.2.717
6. Bader, P. L., Faizi, M., Kima, L. H., Owen, S. F., Tadross, M. R., Alfa, R. W., et al. (2011). Mouse model of Timothy syndrome recapitulates triad of autistic traits. Proc. Natl. Acad. Sci. U.S.A. 108, 15432-15437. doi: 10.1073/pnas.1112667108
7. Bagal, S. K., Chapman, M. L., Marron, B. E., Prime, R., Storer, R. I., and Swain, N. A. (2014). Recent progress in sodium channel modulators for pain. Bioorg. Med. Chem. Lett. 24, 3690-3699. doi: 10.1016/j.bmcl.2014.06.038
8. Barlassina, C., Dal Fiume, C., Lanzani, C., Manunta, P., Guffanti, G., Ruello, A., et al. (2007). Common genetic variants and haplotypes in renal CLCNKA gene are associated to salt-sensitive hypertension. Hum. Mol. Genet. 16, 1630-1638. doi: 10.1093/hmg/ddm112
9. Baron, A., and Lingueglia, E. (2015). Pharmacology of acid-sensing ion channels-Physiological and therapeutical perspectives. Neuropharmacology 94, 19-35. doi: 10.1016/j.neuropharm.2015.01.005
10. Baruscotti, M., Bucchi, A., Milanesi, R., Paina, M., Barbuti, A., Gnecchi-Ruscone, T., et al. (2015). A gain-of-function mutation in the cardiac pacemaker HCN4 channel increasing cAMP sensitivity is associated with familial Inappropriate Sinus Tachycardia. Eur. Heart J. pii: ehv582. doi: 10.1093/eurheartj/ehv582 [Epub ahead of print].
11. Batla, A., Pandey, S., and Nehru, R. (2011). Megalencephalic leukoencephalopathy with subcortical cysts: a report of four cases. J. Pediatr. Neurosci. 6, 74-77. doi: 10.4103/1817-1745.84416
12. Bechi, G., Rusconi, R., Cestèle, S., Striano, P., Franceschetti, S., and Mantegazza, M. (2015). Rescuable folding defective NaV1.1 (SCN1A) mutants in epilepsy: properties, occurrence, and novel rescuing strategy with peptides targeted to the endoplasmic reticulum. Neurobiol. Dis. 75, 100-114. doi: 10.1016/j.nbd.2014.12.028
13. Bendahhou, S., Cummins, T. R., Griggs, R. C., Fu, Y. H., and Ptácek, L. J. (2001). Sodium channel inactivation defects are associated with acetazolamide-exacerbated hypokalemic periodic paralysis. Ann. Neurol. 50, 417-420. doi: 10.1002/ana.1144
14. Bender, A. C., Morse, R. P., Scott, R. C., Holmes, G. L., and Lenck-Santini, P. P. (2012). SCN1A mutations in Dravet syndrome: impact of interneuron dysfunction on neural networks and cognitive outcome. Epilepsy Behav. 23, 177-186. doi: 10.1016/j.yebeh.2011.11.022
15. Bennett, D. L. H., and Woods, C. G. (2014). Painful and painless channelopathies. Lancet Neurol. 13, 587-599. doi: 10.1016/S1474-4422(14)70024-9
16. Benstead, T. J., Camfield, P. R., and King, D. B. (1987). Treatment of paramyotonia congenita with acetazolamide. Can. J. Neurol. Sci. 14, 156-158.
17. Berkovic, S. F., Heron, S. E., Giordano, L., Marini, C., Guerrini, R., Kaplan, R. E., et al. (2004). Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy. Ann. Neurol. 55, 550-557. doi: 10.1002/ana.20029
18. Betzenhauser, M. J., Pitt, G. S., and Antzelevitch, C. (2015). Calcium channel mutations in cardiac arrhythmia syndromes. Curr. Mol. Pharmacol. 8, 133-142. doi: 10.2174/1874467208666150518114857
19. Blanz, J., Schweizer, M., Auberson, M., Maier, H., Muenscher, A., Hübner, C. A., et al. (2007). Leukoencephalopathy upon disruption of the chloride channel ClC-2. J. Neurosci. 27, 6581-6589. doi: 10.1523/JNEUROSCI.0338-07.2007
20. Bockenhauer, D., Feather, S., Stanescu, H. C., Bandulik, S., Zdebik, A. A., Reichold, M., et al. (2009). Epilepsy, ataxia, sensorineural deafness, tubulopathy, and KCNJ10 mutations. N. Engl. J. Med. 360, 1960-1970. doi: 10.1056/NEJMoa0810276
21. Boim, M. A., Ho, K., Shuck, M. E., Bienkowski, M. J., Block, J. H., Slightom, J. L., et al. (1995). ROMK inwardly rectifying ATP-sensitive K+ channel. II. Cloning and distribution of alternative forms. Am. J. Physiol. 268, F1132-F1140.
22. Brignone, M. S., Lanciotti, A., Camerini, S., De Nuccio, C., Petrucci, T. C., Visentin, S., et al. (2015). MLC1 protein: a likely link between leukodystrophies and brain channelopathies. Front. Cell. Neurosci. 9:66. doi: 10.3389/fncel.2015.00106
23. Brochard, K., Boyer, O., Blanchard, A., Loirat, C., Niaudet, P., Macher, M. A., et al. (2009). Phenotype-genotype correlation in antenatal and neonatal variants of Bartter syndrome. Nephrol. Dial. Transplant. 24, 1455-1464. doi: 10.1093/ndt/gfn689
24. Brouwer, B. A., Merkies, I. S., Gerrits, M. M., Waxman, S. G., Hoeijmakers, J. G., and Faber, C. G. (2014). Painful neuropathies: the emerging role of sodium channelopathies. J. Peripher. Nerv. Syst. 19, 53-65. doi: 10.1111/jns5.12071
25. Brugada, R., Hong, K., Dumaine, R., Cordeiro, J., Gaita, F., Borggrefe, M., et al. (2004). Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109, 30-35. doi: 10.1161/01.CIR.0000109482.92774.3A
26. Campuzano, O., Sarquella-Brugada, G., Brugada, R., and Brugada, J. (2015). Genetics of channelopathies associated with sudden cardiac death. Global Cardiol. Sci. Pract. 2015:39. doi: 10.5339/gcsp.2015.39
27. Cannon, S. C. (2015). Channelopathies of skeletal muscle excitability. Compr. Physiol. 5, 761-790. doi: 10.1002/cphy.c140062
28. Cao, Y., Pang, J., and Zhou, P. (2015). HCN channels as therapeutic targets for heart failure and pain. Curr. Top. Med. Chem. doi: 10.2174/1568026616666151215104058 [Epub ahead of print].
29. Capulli, M., Maurizi, A., Ventura, L., Rucci, N., and Teti, A. (2015). Effective Small Interfering RNA Therapy to Treat CLCN7-dependent Autosomal Dominant Osteopetrosis Type 2. Mol. Ther. Nucleic Acids 4:e248. doi: 10.1038/mtna.2015.21
30. Carbonara, R., Carocci, A., Roussel, J., Crescenzo, G., Buonavoglia, C., Franchini, C., et al. (2015). Inhibition of voltage-gated sodium channels by sumatriptan bioisosteres. Front. Pharmacol. 6:155. doi: 10.3389/fphar.2015.00155
31. Cardani, R., Giagnacovo, M., Botta, A., Rinaldi, F., Morgante, A., Udd, B., et al. (2012). Co-segregation of DM2 with a recessive CLCN1 mutation in juvenile onset of myotonic dystrophy type 2. J. Neurol. 259, 2090-2099. doi: 10.1007/s00415-012-6462-1
32. Carocci, A., Catalano, A., Bruno, C., Lentini, G., Franchini, C., De Bellis, M., et al. (2010). Synthesis, and in vitro sodium channel blocking activity evaluation of novel homochiral mexiletine analogue. Chirality 22, 299-307. doi: 10.1002/chir.20741
33. Catterall, W. A. (2012). Voltage-gated sodium channels at 60: structure, function and pathophysiology. J. Physiol. 590, 2577-2589. doi: 10.1113/jphysiol.2011.224204
34. Catterall, W. A. (2014). Sodium channels, inherited epilepsy, and antiepileptic drugs. Annu. Rev. Pharmacol. Toxicol. 54, 317-338. doi: 10.1146/annurev-pharmtox-011112-140232
35. Catterall, W. A., and Swanson, T. M. (2015). Structural basis for pharmacology of voltage-gated sodium and calcium channels. Mol. Pharmacol. 88, 141-150. doi: 10.1124/mol.114.097659
36. Cebotaru, V., Kaul, S., Devuyst, O., Cai, H., Racusen, L., Guggino, W. B., et al. (2005). High citrate diet delays progression of renal insufficiency in the ClC-5 knockout mouse model of Dent's disease. Kidney Int. 68, 642-652. doi: 10.1111/j.1523-1755.2005.00442.x
37. Cestèle, S., Schiavon, E., Rusconi, R., Franceschetti, S., and Mantegazza, M. (2013). Nonfunctional Nav1.1 familial hemiplegic migraine mutant transformed into gain of function by partial rescue of folding defects. Proc. Natl. Acad. Sci. U.S.A. 110, 17546-17551. doi: 10.1073/pnas.1309827110
38. Chen, Q., Kirsch, G. E., Zhang, D., Brugada, R., Brugada, J., Brugada, P., et al. (1998). Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 392, 293-296. doi: 10.1038/33305
39. Chen, T. T., Klassen, T. L., Goldman, A. M., Marini, C., Guerrini, R., and Noebels, J. L. (2013). Novel brain expression of ClC-1 chloride channels and enrichment of CLCN1 variants in epilepsy. Neurology 80, 1078-1085. doi: 10.1212/WNL.0b013e31828868e7
40. Chen, Y., Lu, J., Pan, H., Zhang, Y., Wu, H., Xu, K., et al. (2003). Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann. Neurol. 54, 239-243. doi: 10.1002/ana.10607
41. Chen, Y., Yu, F. H., Sharp, E. M., Beacham, D., Scheuer, T., and Catterall, W. A. (2008). Functional properties and differential neuromodulation of Na(v)1.6 channels. Mol. Cell. Neurosci. 38, 607-615. doi: 10.1016/j.mcn.2008.05.009
42. Cheng, C. J., Lin, S. H., Lo, Y. F., Yang, S. S., Hsu, Y. J., Cannon, S. C., et al. (2011). Identification and functional characterization of Kir2.6 mutations associated with non-familial hypokalemicperiodic paralysis. J. Biol. Chem. 286, 27425-27435. doi: 10.1074/jbc.M111.249656
43. Choi, J. S., Zhang, L., Dib-Hajj, S. D., Han, C., Tyrrell, L., Lin, Z., et al. (2009). Mexiletine-responsive erythromelalgia due to a new Nav1.7 mutation showing use-dependent current fall-off. Exp. Neurol. 216, 383-389. doi: 10.1016/j.expneurol.2008.12.012
44. Cox, J. J., Reimann, F., Nicholas, A. K., Thornton, G., Roberts, E., Springell, K., et al. (2006). An SCN9A channelopathy causes congenital inability to experience pain. Nature 444, 894-898. doi: 10.1038/nature05413
45. Cross, J. H., Arora, R., Heckemann, R. A., Gunny, R., Chong, K., Carr, L., et al. (2013). Neurological features of epilepsy, ataxia, sensorineural deafness, tubulopathy syndrome. Dev. Med. Child. Neurol. 55, 846-856. doi: 10.1111/dmcn.12171
46. D'Adamo, M. C., Gallenmüller, C., Servettini, I., Hartl, E., Tucker, S. J., Arning, L., et al. (2015a). Novel phenotype associated with a mutation in the KCNA1(Kv1.1) gene. Front. Physiol. 5:525. doi: 10.3389/fphys.2014.00525
47. D'Adamo, M. C., Hasan, S., Guglielmi, L., Servettini, I., Cenciarini, M., Catacuzzeno, L., et al. (2015b). New insights into the pathogenesis and therapeutics of episodic ataxia type 1. Front. Cell. Neurosci. 9:317. doi: 10.3389/fncel.2015.00317
48. Davies, N. P., Imbrici, P., Fialho, D., Herd, C., Bilsland, L. G., Weber, A., et al. (2005). Andersen-Tawil syndrome: new potassium channel mutations and possible phenotypic variation. Neurology 65, 1083-1089. doi: 10.1212/01.wnl.0000178888.03767.74
49. Davis, M. D., and Sandroni, P. (2005). Lidocaine patch for pain of erythromelalgia: follow-up of 34 patients. Arch. Dermatol. 141, 1320-1321.
50. De Bellis, M., De Luca, A., Desaphy, J. F., Carbonara, R., Heiny, J. A., Kennedy, A., et al. (2013). Combined modifications of mexiletine pharmacophores for new lead blockers of Nav1.4 channels. Biophys. J. 104, 344-354. doi: 10.1016/j.bpj.2012.11.3830
51. De Franco, E., Flanagan, S. E., Houghton, J. A., Lango, A. H., Mackay, D. J., Temple, I. K., et al. (2015). The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study. Lancet 386, 957-963. doi: 10.1016/S0140-6736(15)60098-8
52. de Lera Ruiz, M., and Kraus, R. L. (2015). Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications. J. Med. Chem. 58, 7093-7118. doi: 10.1021/jm501981g
53. De Luca, A. (2012). Pre-clinical drug tests in the mdx mouse as a model of dystrophinopathies: an overview. Acta Myol. 31, 40-47.
54. De Luca, A., Pierno, S., Liantonio, A., Camerino, C., and Conte Camerino, D. (1998). Phosphorylation and IGF-1-mediated dephosphorylation pathways control the activity and the pharmacological properties of skeletal muscle chloride channels. Br. J. Pharmacol. 125, 477-482. doi: 10.1038/sj.bjp.0702107
55. De Luca, A., Pierno, S., Liantonio, A., Cetrone, M., Camerino, C., Fraysse, B., et al. (2003). Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J. Pharmacol. Exp. Ther. 304, 453-463. doi: 10.1124/jpet.102.041343
56. De Luca, A., Pierno, S., Liantonio, A., Desaphy, J. F., Natuzzi, F., Didonna, M. P., et al. (2004). New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on myotonic ADR mouse. Neuromuscul. Disord. 14, 405-416. doi: 10.1016/j.nmd.2004.04.006
57. De Luca, A., Tricarico, D., Wagner, R., Bryant, S. H., Tortorella, V., and Conte Camerino, D. (1992). Opposite effects of enantiomers of clofibric acid derivative on rat skeletal muscle chloride conductance: antagonism studies and theoretical modeling of two different receptor site interactions. J. Pharmacol. Exp. Ther. 260, 364-368.
58. de Pablos, A. L., García-Nieto, V., López-Menchero, J. C., Ramos-Trujillo, E., González-Acosta, H., and Claverie-Martín, F. (2014). Severe manifestation of Bartter syndrome Type IV caused by a novel insertion mutation in the BSND gene. Clin. Nephrol. 81, 363-368. doi: 10.5414/CN107687
59. Depienne, C., Bugiani, M., Dupuits, C., Galanaud, D., Touitou, V., Postma, N., et al. (2013). Brain white matter oedema due to ClC-2 chloride channel deficiency: an observational and alytical study. Lancet Neurol. 12, 659-668. doi: 10.1016/S1474-4422(13)70053-X
60. Desaphy, J.-F., Carbonara, R., Costanza, T., and Conte Camerino, D. (2014). Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses new promising antimyotonic drugs. Exp. Neurol. 255, 96-102. doi: 10.1016/j.expneurol.2014.02.023
61. Desaphy, J. F., Carbonara, R., Costanza, T., Lentini, G., Cavalluzzi, M. M., Bruno, C., et al. (2013a). Molecular dissection of lubeluzole use-dependent block of voltage-gated sodium channels discloses new therapeutic potentials. Mol. Pharmacol. 83, 406-415. doi: 10.1124/mol.112.080804
62. Desaphy, J. F., De Luca, A., Didonna, M. P., George, A. L. Jr., and Conte Camerino, D. (2004). Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block. J. Physiol. 554, 321-334. doi: 10.1113/jphysiol.2003.046995
63. Desaphy, J. F., De Luca, A., Tortorella, P., De Vito, D., George, A. L. Jr., and Conte, C. D. (2001). Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative. Neurology 57, 1849-1857. doi: 10.1212/WNL.57.10.1849
64. Desaphy, J. F., Gramegna, G., Altamura, C., Dinardo, M. M., Imbrici, P., George Jr., et al. (2013b). Functional characterization of ClC-1 mutations from patients affected by recessive myotonia congenita presenting with different clinical phenotypes. Exp. Neurol. 248, 530-540. doi: 10.1016/j.expneurol.2013.07.018
65. Desaphy, J. F., Modoni, A., Lomonaco, M., and Conte Camerino, D. (2013c). Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy. Eur. J. Clin. Pharmacol. 69, 1037-1039. doi: 10.1007/s00228-012-1414-3
66. Dichgans, M., Freilinger, T., Eckstein, G., Babini, E., Lorenz-Depiereux, B., Biskup, S., et al. (2005). Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 366, 371-377. doi: 10.1016/S0140-6736(05)66786-4
67. Diener, H. C., Solbach, K., Holle, D., and Gaul, C. (2015). Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options. Clin. Med. (Lond). 15, 344-350. doi: 10.7861/clinmedicine.15-4-344
68. Diep, V., and Seaver, L. H. (2015). Long QT syndrome with craniofacial, digital, and neurologic features: is it useful to distinguish between timothy syndrome types 1 and 2? Am. J. Med. Genet. A. 167A, 2780-2785. doi: 10.1002/ajmg.a.37258
69. Dinardo, M. M., Camerino, G., Mele, A., Latorre, R., Conte Camerino, D., and Tricarico, D. (2012). Splicing of the rSlo gene affects the molecular composition and drug response of Ca2+-activated K+ channels in skeletal muscle. PLoS ONE 7:e40235. doi: 10.1371/journal.pone.0040235
70. Duarri, A., Jezierska, J., Fokkens, M., Meijer, M., Schelhaas, H. J., den Dunnen, W. F., et al. (2012). Mutations in potassium channel kcnd3 cause spinocerebellar ataxia type 19. Ann. Neurol. 72, 870-880. doi: 10.1002/ana.23700
71. Eckle, V. S., Shcheglovitov, A., Vitko, I., Dey, D., Yap, C. C., Winckler, B., et al. (2014). Mechanisms by which a CACNA1H mutation in epilepsy patients increases seizure susceptibility. J. Physiol. 592, 795-809. doi: 10.1113/jphysiol.2013.264176
72. Eguchi, H., Tsujino, A., Kaibara, M., Hayashi, H., Shirabe, S., Taniyama, K., et al. (2006). Acetazolamide acts directly on the human skeletal muscle chloride channel. Muscle Nerve 34, 292-297. doi: 10.1002/mus.20585
73. El-Sherif, N., and Boutjdir, M. (2015). Role of pharmacotherapy in cardiac ion channelopathies. Pharmacol. Ther. 155, 132-142. doi: 10.1016/j.pharmthera.2015.09.002
74. Estacion, M., Vohra, B. P., Liu, S., Hoeijmakers, J., Faber, C. G., Merkies, I. S., et al. (2015). Ca2+ toxicity due to reverse Na+/Ca2+ exchange contributes to degeneration of neurites of DRG neurons induced by a neuropathy-associated Nav1.7 mutation. J. Neurophysiol. 114, 1554-1564. doi: 10.1152/jn.00195.2015
75. Estévez, R., Boettger, T., Stein, V., Birkenhäger, R., Otto, E., Hildebrandt, F., et al. (2001). Barttin is a Cl-channel beta-subunit crucial for renal Cl-reabsorption and inner ear K+ secretion. Nature 414, 558-561. doi: 10.1038/35107099
76. Faber, C. G., Hoeijmakers, J. G., Ahn, H. S., Cheng, X., Han, C., Choi, J. S., et al. (2012a). Gain of function Na(V) 1.7 mutations in idiopathic small fiber neuropathy. Ann. Neurol. 71, 26-39. doi: 10.1002/ana.22485
77. Faber, C. G., Lauria, G., Merkies, I. S., Cheng, X., Han, C., Ahn, H. S., et al. (2012b). Gain-of-function Nav1.8 mutations in painful neuropathy. Proc. Natl. Acad. Sci. U.S.A. 109, 19444-19449. doi: 10.1073/pnas.1216080109
78. Feng, L., Campbell, E. B., Hsiung, Y., and MacKinnon, R. (2010). Structure of a eukaryotic CLC transporter defines an intermediate state in the transport cycle. Science 330, 635-641. doi: 10.1126/science.1195230
79. Fertleman, C. R., Baker, M. D., Parker, K. A., Moffatt, S., Elmslie, F. V., Abrahamsen, B., et al. (2006). SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron 52, 767-774. doi: 10.1016/j.neuron.2006.10.006
80. Fertleman, C. R., Ferrie, C. D., Aicardi, J., Bednarek, N. A., Eeg-Olofsson, O., Elmslie, F. V., et al. (2007). Paroxysmal extreme pain disorder (previously familial rectal pain syndrome). Neurology 69, 586-595. doi: 10.1212/01.wnl.0000268065.16865.5f
81. Finnerup, N. B., Attal, N., Haroutounian, S., McNicol, E., Baron, R., Dworkin, R. H., et al. (2015). Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 14, 162-173. doi: 10.1016/S1474-4422(14)70251-0
82. Fischer, T. Z., Gilmore, E. S., Estacion, M., Eastman, E., Taylor, S., Melanson, M., et al. (2009). A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia. Ann. Neurol. 65, 733-741. doi: 10.1002/ana.21678
83. Fratta, P., and Hanna, M. G. (2015). Neuromuscular diseases: progress in gene discovery drives diagnostics and therapeutics. Lancet Neurol. 14, 13-14. doi: 10.1016/S1474-4422(14)70239-X
84. Furby, A., Vicart, S., Camdessanché, J. P., Fournier, E., Chabrier, S., Lagrue, E., et al. (2014). Heterozygous CLCN1 mutations can modulate phenotype in sodium channel myotonia. Neuromuscul. Disord. 24, 953-959. doi: 10.1016/j.nmd.2014.06.439
85. Gaita, F., Giustetto, C., Bianchi, F., Schimpf, R., Haissaguerre, M., Calò, L., et al. (2004). Short QT syndrome: pharmacological treatment. J. Am. Coll. Cardiol. 43, 1494-1499.
86. Garcia, M. L., and Kaczorowski, G. J. (2014). Targeting the inward-rectifier potassium channel ROMK in cardiovascular disease. Curr. Opin. Pharmacol. 15, 1-6. doi: 10.1016/j.coph.2013.11.005
87. Garcia, M. L., Priest, B. T., Alonso-Galicia, M., Zhou, X., Felix, J. P., Brochu, R. M., et al. (2014). Pharmacologic inhibition of the renal outer medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresis. J. Pharmacol. Exp. Ther. 348, 153-164. doi: 10.1124/jpet.113.208603
88. Ghelardini, C., Desaphy, J. F., Muraglia, M., Corbo, F., Matucci, R., Dipalma, A., et al. (2010). Effects of a new potent analog of tocainide on hNav1.7 sodium channels and in vivo neuropathic pain models. Neuroscience 169, 863-873. doi: 10.1016/j.neuroscience.2010.05.019
89. Giudicessi, J. R., and Ackerman, M. J. (2013). Genotype-and phenotype-guided management of congenital long QT syndrome. Curr. Probl. Cardiol. 38, 417-455. doi: 10.1016/j.cpcardiol.2013.08.001
90. Glauser, T. A., Cnaan, A., Shinnar, S., Hirtz, D. G., Dlugos, D., Masur, D., et al. (2013). Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia 54, 141-155. doi: 10.1111/epi.12028
91. Graves, T. D., Imbrici, P., Kors, E. E., Terwindt, G. M., Eunson, L. H., Frants, R. R., et al. (2008). Premature stop codons in a facilitating EF-hand splice variant of CaV2.1 cause episodic ataxia type 2. Neurobiol. Dis. 32, 10-15. doi: 10.1016/j.nbd.2008.06.002
92. Grunnet, M., Strøbæk, D., Hougaard, C., and Christophersen, P. (2014). Kv7 channels as targets for anti-epileptic and psychiatric drug-development. Eur. J. Pharmacol. 726, 133-137. doi: 10.1016/j.ejphar.2014.01.017
93. Guglielmi, L., Servettini, I., Caramia, M., Catacuzzeno, L., Franciolini, F., D'Adamo, M. C., et al. (2014). Update on the implication of potassium channels in autism: K+ channelautism spectrum disorder. Front. Cell. Neurosci. 9:34. doi: 10.3389/fncel.2015.00034
94. Habbout, K., Poulin, H., Rivier, F., Giuliano, S., Sternberg, D., Fontaine, B., et al. (2016). A recessive Nav1.4 mutation underlies congenital myasthenic syndrome with periodic paralysis. Neurology 86, 161-169. doi: 10.1212/WNL.0000000000002264
95. Habib, A. M., Wood, J. N., and Cox, J. J. (2015). Sodium Channels and Pain. Handb. Exp. Pharmacol. 227, 39-56. doi: 10.1007/978-3-662-46450-2_3
96. Han, C., Vasylyev, D., Macala, L. J., Gerrits, M. M., Hoeijmakers, J. G., Bekelaar, K. J., et al. (2014). The G1662S NaV1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitability. J. Neurol. Neurosurg. Psychiatry 85, 499-505. doi: 10.1136/jnnp-2013-306095
97. Havakuk, O., and Viskin, S. (2016). A Tale of 2 Diseases: the history of long-QT syndrome and brugada syndrome. J. Am. Coll. Cardiol. 67, 100-108. doi: 10.1016/j.jacc.2015.10.020
98. Herson, P. S., Virk, M., Rustay, N. R., Bond, C. T., Crabbe, J. C., Adelman, J. P., et al. (2003). A mouse model of episodic ataxia type-1. Nat. Neurosci. 6, 378-383. doi: 10.1038/nn1025
99. Heyes, S., Pratt, W. S., Rees, E., Dahimene, S., Ferron, L., Owen, M. J., et al. (2015). Genetic disruption of voltage-gated calcium channels in psychiatric and neurological disorders. Prog. Neurobiol. 134, 36-54. doi: 10.1016/j.pneurobio.2015.09.002
100. Hibino, H., Inanobe, A., Furutani, K., Murakami, S., Findlay, I., and Kurachi, Y. (2010). Inwardly rectifying potassium channels: their structure, function, and physiological roles. Physiol. Rev. 90, 291-366. doi: 10.1152/physrev.00021.2009
101. Hodgin, J. B., Corey, H. E., Kaplan, B. S., and D'Agati, V. D. (2008). Dent disease presenting as partial Fanconi syndrome and hypercalciuria. Kidney Int. 73, 1320-1323. doi: 10.1038/sj.ki.5002785
102. Hoegg-Beiler, M. B., Sirisi, S., Orozco, I. J., Ferrer, I., Hohensee, S., Auberson, M., et al. (2014). Disrupting MLC1 and GlialCAM and ClC-2 interactions in leukodystrophy entails glial chloride channel dysfunction. Nat. Commun. 5:3475. doi: 10.1038/ncomms4475
103. Hoffmann, E. K., Sørensen, B. H., Sauter, D. P., and Lambert, I. H. (2015). Role of volume-regulated and calcium-activated anion channels in cell volume homeostasis, cancer and drug resistance. Channels (Austin) 9, 380-396. doi: 10.1080/19336950.2015.1089007
104. Huang, J., Han, C., Estacion, M., Vasylyev, D., Hoeijmakers, J. G., Gerrits, M. M., et al. (2014). Gain-of-function sodium channel Nav1.9 mutations in painful neuropathy. Brain 137, 1627-1642. doi: 10.1093/brain/awu079
105. Humphries, E. S., and Dart, C. (2015). Neuronal and cardiovascular potassium channels as therapeutic drug targets: promise and pitfalls. J. Biomol. Screen. 20, 1055-1073. doi: 10.1177/1087057115601677
106. Igelström, K. M., and Heyward, P. M. (2012). The antidepressant drug fluoxetine inhibits persistent sodium currents and seizure-like events. Epilepsy Res. 101, 174-181. doi: 10.1016/j.eplepsyres.2012.03.019
107. Ilg, W., Bastian, A. J., Boesch, S., Burciu, R. G., Celnik, P., Claaben, J., et al. (2014). Consensus paper: management of degenerative cerebellar disorders. Cerebellum 13, 248-268. doi: 10.1007/s12311-013-0531-6
108. Imbrici, P., Altamura, C., Pessia, M., Mantegazza, R., Desaphy, J. F., and Conte Camerino, D. (2015a). ClC-1 chloride channels: state-of-the-art research and future challenges. Front. Cell. Neurosci. 9:156. doi: 10.3389/fncel.2015.00156
109. Imbrici, P., D'Adamo, M. C., Grottesi, A., Biscarini, A., and Pessia, M. (2011). Episodic ataxia type 1 mutations affect fast inactivation of K+ channels by a reduction in either subunit surface expression or affinity for inactivation domain. Am. J. Physiol. Cell. Physiol. 300, C1314-C1322. doi: 10.1152/ajpcell.00456.2010
110. Imbrici, P., Liantonio, A., Gradogna, A., Pusch, M., and Camerino, D. C. (2014). Targeting kidney CLC-K channels: pharmacological profile in a human cell line versus Xenopus oocytes. Biochim. Biophys. Acta 1838, 2484-2491. doi: 10.1016/j.bbamem.2014.05.017
111. Imbrici, P., Maggi, L., Mangiatordi, G. F., Dinardo, M. M., Altamura, C., Brugnoni, R., et al. (2015b). ClC-1 mutations in myotonia congenita patients: insights into molecular gating mechanisms and genotype-phenotype correlation. J. Physiol. 593, 4181-4199. doi: 10.1113/JP270358
112. Jan, L. Y., and Jan, Y. N. (2012). Voltage-gated potassium channels and the diversity of electrical congenita. J. Physiol. 590, 2591-2599. doi: 10.1113/jphysiol.2011.224212
113. Janssen, A. G., Scholl, U., Domeyer, C., Nothmann, D., Leinenweber, A., and Fahlke, C. (2009). Disease-causing dysfunctions of barttin in Bartter syndrome type IV. J. Am. Soc. Nephrol. 20, 145-153. doi: 10.1681/ASN.2008010102
114. Jarecki, B. W., Piekarz, A. D., Jackson, I. I. J. O., and Cummins, T. R. (2010). Human voltage-gated sodium channel mutations that cause inherited neuronal and muscle channelopathies increase resurgent sodium currents. J. Clin. Invest. 120, 369-378. doi: 10.1172/JCI40801
115. Jen, J. C. (2015). "Familial Hemiplegic Migraine, " in GeneReviews [Internet], eds R. A. Pagon, M. P. Adam, H. H. Ardinger, H. H. Ardinger, S. E. Wallace, A. Amemiya, et al. (Seattle, WA: University of Washington).
116. Jen, J. C., Graves, T. D., Hess, E. J., Hanna, M. G., Griggs, R. C., Baloh, R. W., et al. (2007). Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain 130, 2484-2493. doi: 10.1093/brain/awm126
117. Jentsch, T. J. (2015). Discovery of CLC transport proteins: cloning, structure, function and pathophysiology. J. Physiol. 593, 4091-4109. doi: 10.1113/JP270043
118. Jongjaroenprasert, W., Phusantisampan, T., Mahasirimongkol, S., Mushiroda, T., Hirankarn, N., Snabboon, T., et al. (2012). A genome-wide association study identifies novel susceptibility genetic variation for thyrotoxic hypokalemicperiodic paralysis. J. Hum. Genet. 57, 301-304. doi: 10.1038/jhg.2012.20
119. Kaneko, Y., and Szallasi, A. (2014). Transient receptor potential (TRP) channels: a clinical perspective. Br. J. Pharmacol. 171, 2474-2507. doi: 10.1111/bph.12414
120. Kasper, D., Planells-Cases, R., Fuhrmann, J. C., Scheel, O., Zeitz, O., Ruether, K., et al. (2005). Loss of the chloride channel ClC-7 leads to lysosomal storage disease and neurodegeneration. EMBO J. 24, 1079-1091. doi: 10.1038/sj.emboj.7600576
121. Kearney, J. A. (2011). Genetic modifiers of neurological disease. Curr. Opin. Genet. Dev. 21, 349-353. doi: 10.1016/j.gde.2010.12.007
122. Key, L. L. Jr., Rodriguiz, R. M., Willi, S. M., Wright, N. M., Hatcher, H. C., Eyre, D. R., et al. (1995). Long-term treatment of osteopetrosis with recombinant human interferon gamma. N. Engl. J. Med. 332, 1594-1599. doi: 10.1056/NEJM199506153322402
123. Khogali, S., Lucas, B., Ammar, T., Dejong, D., Barbalinardo, M., Hayward, L. J., et al. (2015). Physiological basis for muscle stiffness and weakness in a knock-in M1592V mouse model of hyperkalemic periodic paralysis. Physiol. Rep. 3:e12656. doi: 10.14814/phy2.12656
124. Kim, J. B., Kim, M. H., Lee, S. J., Kim, D. J., and Lee, B. C. (2007). The genotype and clinical phenotype of Korean patients with familial hypokalemic periodic paralysis. J. Korean Med. Sci. 22, 946-951. doi: 10.3346/jkms.2007.22.6.946
125. Kokunai, Y., Nakata, T., Furuta, M., Sakata, S., Kimura, H., Aiba, T., et al. (2014). A Kir3.4 mutation causes Andersen-Tawil syndrome by an inhibitory effect on Kir2.1. Neurology 82, 1058-1064. doi: 10.1212/WNL.0000000000000239
126. Kornak, U., Kasper, D., Bösl, M. R., Kaiser, E., Schweizer, M., Schulz, A., et al. (2001). Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 104, 205-215. doi: 10.1016/S0092-8674(01)00206-9
127. Kornilov, P., Peretz, A., and Attali, B. (2013). Channel gating pore: a new therapeutic target. Cell Res. 23, 1067-1068. doi: 10.1038/cr.2013.89
128. Krämer, B. K., Bergler, T., Stoelcker, B., and Waldegger, S. (2008). Mechanisms of Disease: the kidney-specific chloride channels ClCKA and ClCKB, the Barttin subunit, and their clinical relevance. Nat. Clin. Pract. Nephrol. 4, 38-46. doi: 10.1038/ncpneph0689
129. Kremeyer, B., Lopera, F., Cox, J. J., Momin, A., Rugiero, F., Marsh, S., et al. (2010). A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. Neuron 66, 671-680. doi: 10.1016/j.neuron.2010.04.030
130. Krey, J. F., Pasca, S. P., Shcheglovitov, A., Yazawa, M., Schwemberger, R., and Rasmusson, R. (2013). Timothy syndrome is associated with activity-dependent dendritic retraction in rodent and human neurons. Nat. Neurosci. 16, 201-209. doi: 10.1038/nn.3307
131. Kullmann, D. M., and Waxmann, S. G. (2010). Neurological channelopathies: new insights into disease mechanisms and ion channel function. J. Physiol. 588, 1823-1827. doi: 10.1113/jphysiol.2010.190652
132. Lampert, A., Eberhardt, M., and Waxman, S. G. (2014). Altered sodium channel gating as molecular basis of pain: contribution of activation, inactivation, and resurgent currents. Handb. Exp. Pharmacol. 221, 91-110. doi: 10.1007/978-3-642-41588-3_5
133. Larsen, J., Carvill, G. L., Gardella, E., Kluger, G., Schmiedel, G., Barisic, N., et al. (2015). The phenotypic spectrum of SCN8A encephalopathy. Neurology 84, 480-489. doi: 10.1212/wnl.0000000000001211
134. Lau, E., Correia, C., Freitas, P., Nogueira, C., Costa, M., Saavedra, A., et al. (2015). Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea. Arch. Endocrinol. Metab. 59, 559-561. doi: 10.1590/2359-3997000000076
135. Lee, Y. C., Durr, A., Majczenko, K., Huang, Y. H., Liu, Y. C., Lien, C. C., et al. (2012). Mutations in KCND3 cause spinocerebellar ataxia type 22. Ann. Neurol. 72, 859-869. doi: 10.1002/ana.23701
136. Leipold, E., Hanson-Kahn, A., Frick, M., Gong, P., Bernstein, J. A., Voigt, M., et al. (2015). Cold-aggravated pain in humans caused by a hyperactive NaV1.9 channel mutant. Nat. Commun. 6:10049. doi: 10.1038/ncomms10049
137. Leipold, E., Liebmann, L., Korenke, G. C., Heinrich, T., Giesselmann, S., Baets, J., et al. (2013). A de novo gain-of-function mutation in SCN11A causes loss of pain perception. Nat. Genet. 45, 1399-1404. doi: 10.1038/ng.2767
138. Leisle, L., Ludwig, C. F., Wagner, F. A., Jentsch, T. J., and Stauber, T. (2011). ClC-7 is a slowly voltage-gated 2Cl(-)/1H(+)-exchanger and requires Ostm1 for transport activity. EMBO J. 30, 2140-2152. doi: 10.1038/emboj.2011.137
139. Li, P., Chen, Z., Xu, H., Sun, H., Li, H., Liu, H., et al. (2013). The gating charge pathway of an epilepsy-associated potassium channel accommodates chemical ligands. Cell Res. 23, 1106-1118. doi: 10.1038/cr.2013.82
140. Liantonio, A., Giannuzzi, V., Picollo, A., Babini, E., Pusch, M., and Conte Camerino, D. (2007). Niflumic acid inhibits chloride conductance of rat skeletal muscle by directly inhibiting the CLC-1 channel and by increasing intracellular calcium. Br. J. Pharmacol. 150, 235-247. doi: 10.1038/sj.bjp.0706954
141. Liantonio, A., Gramegna, G., Camerino, G. M., Dinardo, M. M., Scaramuzzi, A., Potenza, M. A., et al. (2012). In-vivo administration of CLC-K kidney chloride channels inhibitors increases water diuresis in rats: a new drug target for hypertension? J. Hypertens. 30, 153-167. doi: 10.1097/HJH.0b013e32834d9eb9
142. Liantonio, A., Imbrici, P., Camerino, G. M., Fracchiolla, G., Carbonara, G., Giannico, D., et al. (2016). Kidney CLC-K chloride channels inhibitors: structure-based studies and efficacy in hypertension and associated CLC-K polymorphisms. J. Hypertens. 34, 981-992. doi: 10.1097/HJH.0000000000000876
143. Liantonio, A., Picollo, A., Carbonara, G., Fracchiolla, G., Tortorella, P., Loiodice, F., et al. (2008). Molecular switch for CLC-K Cl-channel block/activation: optimal pharmacophoric requirements towards high-affinity ligands. Proc. Natl. Acad. Sci. U.S.A. 105, 1369-1373. doi: 10.1073/pnas.0708977105
144. Liao, Y., Anttonen, A. K., Liukkonen, E., Gaily, E., Maljevic, S., Schubert, S., et al. (2010). SCN2A mutation associated with neonatal epilepsy, late-onset episodic ataxia, myoclonus, and pain. Neurology 75, 1454-1458. doi: 10.1212/WNL.0b013e3181f8812e
145. Lim, C. X., Ricos, M. G., Dibbens, L. M., and Heron, S. E. (2016). KCNT1 mutations in seizure disorders: the phenotypic spectrum and functional effects. J. Med. Genet. 53, 217-225. doi: 10.1136/jmedgenet-2015-103508
146. Lion-Francois, L., Mignot, C., Vicart, S., Manel, V., Sternberg, D., Landrieu, P., et al. (2010). Severe neonatal episodic laryngospasm due to de novo SCN4A mutations: a new treatable disorder. Neurology 75, 641-645. doi: 10.1212/WNL.0b013e3181ed9e96
147. Lloyd, S. E., Gunther, W., Pearce, S. H., Thomson, A., Bianchi, M. L., Bosio, M., et al. (1997). Characterisation of renal chloride channel, CLCN5, mutations in hypercalciuric nephrolithiasis (kidney stones) disorders. Hum. Mol. Genet. 6, 1233-1239. doi: 10.1093/hmg/6.8.1233
148. Lo Monaco, M., D'Amico, A., Luigetti, M., Desaphy, J. F., and Modoni, A. (2015). Effect of mexiletine on transitory depression of compound motor action potential in recessive myotonia congenita. Clin. Neurophysiol. 126, 399-403. doi: 10.1016/j.clinph.2014.06.008
149. López-Hernández, T., Ridder, M. C., Montolio, M., Capdevila-Nortes, X., Polder, E., Sirisi, S., et al. (2011). Mutant GlialCAM causes megalencephalic leukoencephalopathy with subcortical cysts, benign familial macrocephaly, and macrocephaly with retardation and autism. Am. J. Hum. Genet. 88, 422-432. doi: 10.1016/j.ajhg.2011.02.009
150. Loudon, K. W., and Fry, A. C. (2014). The renal channelopathies. Ann. Clin. Biochem. 51(Pt 4), 441-458. doi: 10.1177/0004563214531403
151. Mall, M. A., and Galietta, L. J. (2015). Targeting ion channels in cystic fibrosis. J. Cyst. Fibros. 14, 561-570. doi: 10.1016/j.jcf.2015.06.002
152. Mansour-Hendili, L., Blanchard, A., Le Pottier, N., Roncelin, I., Lourdel, S., Treard, C., et al. (2015). Mutation update of the CLCN5 gene responsible for dent disease 1. Hum. Mutat. 36, 743-752. doi: 10.1002/humu.22804
153. Markhorst, J. M., Stunnenberg, B. C., Ginjaar, I. B., Drost, G., Erasmus, C. E., and Sie, L. T. (2014). Clinical experience with long-term acetazolamide treatment in children with nondystrophic myotonias: a three-case report. Pediatr. Neurol. 51, 537-541. doi: 10.1016/j.pediatrneurol.2014.05.027
154. Matthews, E., and Hanna, M. G. (2010). Muscle channelopathies: does the predicted channel gating pore offer new treatment insights for hypokalaemic periodic paralysis? J. Physiol. 588, 1879-1886. doi: 10.1113/jphysiol.2009.186627
155. Matthews, E., and Hanna, M. G. (2014). Repurposing of sodium channel antagonists as potential new anti-myotonic drugs. Exp. Neurol. 261, 812-815. doi: 10.1016/j.expneurol.2014.09.003
156. McCarthy, R. J., Kerns, J. M., Nath, H. A., Shulman, M., and Ivankovich, A. D. (2002). The antinociceptive and histologic effect of sciatic nerve blocks with 5% butamben suspension in rats. Anesth. Analg. 94, 711-716. doi: 10.1097/00000539-200203000-00043
157. McCormack, K., Santos, S., Chapman, M. L., Krafte, D. S., Marron, B. E., West, C. W., et al. (2013). Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels. Proc. Natl. Acad. Sci. U.S.A. 110, E2724-E2732. doi: 10.1073/pnas.1220844110
158. McTaggart, J. S., Clark, R. H., and Ashcroft, F. M. (2010). The role of the KATP channel in glucose homeostasis in health and disease: more than meets the islet. J. Physiol. 588, 3201-3209. doi: 10.1113/jphysiol.2010.191767
159. Mele, A., Calzolaro, S., Cannone, G., Cetrone, M., Conte, D., and Tricarico, D. (2014). Database search of spontaneous reports and pharmacological investigations on the sulfonylureas and glinides-induced atrophy in skeletal muscle. Pharmacol. Res. Perspect. 2:e00028. doi: 10.1002/prp2.28
160. Miceli, F., Soldovieri, M. V., Ambrosino, P., De Maria, M., Manocchio, L., Medoro, A., et al. (2015a). Molecular pathophysiology and pharmacology of the voltage-sensing module of neuronal ion channels. Front. Cell Neurosci. 9:259. doi: 10.3389/fncel.2015.00259
161. Miceli, F., Soldovieri, M. V., Ambrosino, P., De Maria, M., Migliore, M., Migliore, R., et al. (2015b). Early-onset epileptic encephalopathy caused by gain-of-function mutations in the voltage sensor of Kv7.2 and Kv7.3 potassium channel subunits. J. Neurosci. 35, 3782-3793. doi: 10.1523/JNEUROSCI.4423-14.2015
162. Miceli, F., Vargas, E., Bezanilla, F., and Taglialatela, M. (2012). Gating currents from Kv7 channels carrying neuronal hyperexcitability mutations in the voltage-sensing domain. Biophys. J. 102, 1372-1382. doi: 10.1016/j.bpj.2012.02.004
163. Milanesi, R., Bucchi, A., and Baruscotti, M. (2015). The genetic basis for inherited forms of sinoatrial dysfunction and atrioventricular node dysfunction. J. Interv. Card. Electrophysiol. 43, 121-134. doi: 10.1007/s10840-015-9998-z
164. Miller, I. O., and Sotero de Menezes, M. A. (2014). SCN1A-Related Seizure Disorders. Seattle, WA: University of Washington.
165. Minassian, N. A., Lin, M. C., and Papazian, D. M. (2012). Altered Kv3.3 channel gating in early-onset spinocerebellar ataxia type 13. J. Physiol. 590, 1599-1614. doi: 10.1113/jphysiol.2012.228205
166. Moreau, A., Gosselin-Badaroudine, P., and Chahine, M. (2014). Biophysics, pathophysiology, and pharmacology of ion channel gating pores. Front. Pharmacol. 5:53. doi: 10.3389/fphar.2014.00053
167. Moscatelli, I., Thudium, C. S., Flores, C., Schulz, A., Askmyr, M., Gudmann, N. S., et al. (2013). Lentiviral gene transfer of TCIRG1 into peripheral blood CD34(+) cells restores osteoclast function in infantile malignant osteopetrosis. Bone 57, 1-9. doi: 10.1016/j.bone.2013.07.026
168. Moss, A. J., Zareba, W., Schwarz, K. Q., Rosero, S., McNitt, S., and Robinson, J. L. (2008). Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J. Cardiovasc. Electrophysiol. 19, 1289-1293. doi: 10.1111/j.1540-8167.2008.01246.x
169. Muraglia, M., De Bellis, M., Catalano, A., Carocci, A., Franchini, C., Carrieri, A., et al. (2014). N-Aryl-2, 6-dimethylbenzamides, a new generation of tocainide analogues as blockers of skeletal muscle voltage-gated sodium channels. J. Med. Chem. 57, 2589-2600. doi: 10.1021/jm401864b
170. Nakamura, K., Yoshida, K., Miyazaki, D., Morita, H., and Ikeda, S. (2009). Spinocerebellar ataxia type 6 (SCA6): Clinical pilot trial with gabapentin. J. Neurol. Sci. 278, 107-111. doi: 10.1016/j.jns.2008.12.017
171. Nascimento, C. L., Garcia, C. L., Schvartsman, B. G., and Vaisbich, M. H. (2014). Treatment of Bartter syndrome. Unsolved issue. J. Pediatr. 90, 512-517. doi: 10.1016/j.jped.2014.01.012
172. Nguyen, H. L., Pieper, G. H., and Wilders, R. (2013). Andersen-Tawil syndrome: clinical and molecular aspects. Int. J. Cardiol. 170, 1-16. doi: 10.1016/j.ijcard.2013.10.010
173. Niemeyer, M. I., Cid, L. P., Sepúlveda, F. V., Blanz, J., Auberson, M., and Jentsch, T. J. (2010). No evidence for a role of CLCN2 variants in idiopathic generalized epilepsy. Nat. Genet. 42:3. doi: 10.1038/ng0110-3
174. Nilius, B., and Voets, T. (2013). The puzzle of TRPV4 channelopathies. EMBO Rep. 14, 152-163. doi: 10.1038/embor.2012.219
175. Novak, K. R., Norman, J., Mitchell, J. R., Pinter, M. J., and Rich, M. M. (2015). Sodium channel slow inactivation as a therapeutic target for myotonia congenita. Ann. Neurol. 77, 320-332. doi: 10.1002/ana.24331
176. Novarino, G., Weinert, S., Rickheit, G., and Jentsch, T. J. (2010). Endosomal chloride-proton exchange rather than chloride conductance is crucial for renal endocytosis. Science 328, 1398-1401. doi: 10.1126/science.1188070
177. Oakley, J. C., Cho, A. R., Cheah, C. S., Scheuer, T., and Catterall, W. A. (2013). Synergistic GABA-enhancing therapy against seizures in a mouse model of Dravet syndrome. J. Pharmacol. Exp. Ther. 345, 215-224. doi: 10.1124/jpet.113.203331
178. Ogiwara, I., Ito, K., Sawaishi, Y., Osaka, H., Mazaki, E., Inoue, I., et al. (2009). De novo mutations of voltage-gated sodium channel alphaII gene SCN2A in intractable epilepsies. Neurology 73, 1046-1053. doi: 10.1212/WNL.0b013e3181b9cebc
179. Ohgi, K., Okamoto, F., Kajiya, H., Sakagami, R., and Okabe, K. (2011). Antibodies against ClC7 inhibit extracellular acidification-induced ClC currents and bone resorption activity in mouse osteoclasts. Naunyn Schmiedebergs Arch. Pharmacol. 383, 79-90. doi: 10.1007/s00210-010-0576-8
180. O'Malley, H. A., and Isom, L. L. (2015). Sodium channel β subunits: emerging targets in channelopathies. Annu. Rev. Physiol. 77, 481-504. doi: 10.1146/annurev-physiol-021014-071846
181. Omata, T., Takanashi, J., Wada, T., Arai, H., and Tanabe, Y. (2011). Genetic diagnosis and acetazolamide treatment of familial hemiplegic migraine. Brain Dev. 33, 332-334. doi: 10.1016/j.braindev.2010.05.006
182. Orchard, P. J., Fasth, A. L., Le Rademacher, J., He, W., Boelens, J. J., Horwitz, E. M., et al. (2015). Hematopoietic stem cell transplantation for infantile osteopetrosis. Blood 126, 270-276. doi: 10.1182/blood-2015-01-625541
183. Pasca, S. P., Panagiotakos, G., and Dolmetsch, R. E. (2014). Generating human neurons in vitro and using them to understand neuropsychiatric disease. Annu. Rev. Neurosci. 37, 479-501. doi: 10.1146/annurev-neuro-062012-170328
184. Pedersen, S. F., Okada, Y., and Nilius, B. (2016). Biophysics and physiology of the volume-regulated anion channel (VRAC)/volume-sensitive outwardly rectifying anion channel (VSOR). Pflugers Arch. doi: 10.1007/s00424-015-1781-6 [Epub ahead of print].
185. Peretz, A., Pell, L., Gofman, Y., Haitin, Y., Shamgar, L., Patrich, E., et al. (2010). Targeting the voltage sensor of Kv7.2 voltage-gated K+ channels with a new gating-modifier. Proc. Natl. Acad. Sci. U.S.A. 107, 15637-15642. doi: 10.1073/pnas.0911294107
186. Picollo, A., and Pusch, M. (2005). Chloride/proton antiporter activity of mammalian CLC proteins ClC-4 and ClC-5. Nature 436, 420-423. doi: 10.1038/nature03720
187. Pierno, S., De Luca, A., Desaphy, J.-F., Fraysse, B., Liantonio, A., Didonna, M. P., et al. (2003). Growth hormone secretagogues modulate the electrical and contractile properties of rat skeletal muscle through a ghrelin-specific receptor. Br. J. Pharmacol. 139, 575-584. doi: 10.1038/sj.bjp.0705284
188. Pierno, S., Tricarico, D., De Luca, A., Campagna, F., Carotti, A., Casini, G., et al. (1994). Effects of taurine analogues on chloride channel conductance of rat skeletal muscle fibers: a structure-activity relationship investigation. Naunyn Schmiedebergs Arch. Pharmacol. 349, 416-421. doi: 10.1007/BF00170889
189. Pietrobon, D. (2010). CaV2.1 channelopathies. Pflugers Arch. 460, 375-393. doi: 10.1007/s00424-010-0802-8
190. Pietrobon, D., and Moskowitz, M. A. (2013). Pathophysiology of migraine. Annu. Rev. Physiol. 75, 365-391. doi: 10.1146/annurev-physiol-030212-183717
191. Pini, J., Rouleau, M., Desnuelle, C., Sacconi, S., and Bendahhou, S. (2016). Modeling andersen's syndrome in human induced pluripotent stem cells. Stem Cells Dev. 25, 151-159. doi: 10.1089/scd.2015.0258
192. Piwon, N., Günther, W., Schwake, M., Bösl, M. R., and Jentsch, T. J. (2000). ClC-5 Cl-channel disruption impairs endocytosis in a mouse model for Dent's disease. Nature 408, 369-373. doi: 10.1038/35042597
193. Portaro, S., Altamura, C., Licata, N., Camerino, G. M., Imbrici, P., Musumeci, O., et al. (2015). Clinical, molecular, and functional characterization of CLCN1 mutations in three families with recessive myotonia congenita. Neuromol. Med. 17, 285-296. doi: 10.1007/s12017-015-8356-8
194. Priori, S. G., Napolitano, C., Memmi, M., Colombi, B., Drago, F., Gasparini, M., et al. (2002). Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 106, 69-74. doi: 10.1161/01.CIR.0000020013.73106.D8
195. Priori, S. G., Wilde, A. A., Horie, M., Cho, Y., Behr, E. R., Berul, C., et al. (2013). Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Europace 15, 1389-1406. doi: 10.1093/europace/eut272
196. Prunetti, P., and Perucca, E. (2011). New and forthcoming anti-epileptic drugs. Curr. Opin. Neurol. 24, 159-164. doi: 10.1097/WCO.0b013e32834479a7
197. Pusch, M., Liantonio, A., Bertorello, L., Accardi, A., De Luca, A., Pierno, S., et al. (2000). Pharmacological characterization of chloride channels belonging to the ClC family by the use of chiral clofibric acid derivatives. Mol. Pharmacol. 58, 498-507.
198. Pusch, M., and Zifarelli, G. (2015). ClC-5: Physiological role and biophysical mechanisms. Cell Calcium 58, 57-66. doi: 10.1016/j.ceca.2014.09.007
199. Raja, K. A., Schurman, S., D'mello, R. G., Blowey, D., Goodyer, P., Van Why, S., et al. (2002). Responsiveness of hypercalciuria to thiazide in Dent's disease. J. Am. Soc. Nephrol. 13, 2938-2944. doi: 10.1097/01.ASN.0000036869.82685.F6
200. Remme, C. A., and Wilde, A. A. M. (2014). Targeting sodium channels in cardiac arrhythmia. Curr. Opin. Pharmacol. 15, 53-60. doi: 10.1016/j.coph.2013.11.014
201. Rogawski, M. A., Tofighy, A., White, H. S., Matagne, A., and Wolff, C. (2015). Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 110, 189-205. doi: 10.1016/j.eplepsyres.2014.11.021
202. Rolim, A. L., Lindsey, S. C., Kunii, I. S., Crispim, F., Moisés, R. C., Maciel, R. M., et al. (2014). The insulin-sensitivity sulphonylurea receptor variant is associated with thyrotoxic paralysis. J. Mol. Endocrinol. 53, 295-301. doi: 10.1530/JME-14-0083
203. Rolland, J. F., Tricarico, D., Laghezza, A., Loiodice, F., Tortorella, V., and Camerino, D. C. (2006). A new benzoxazine compound blocks KATP channels in pancreatic beta cells: molecular basis for tissue selectivity in vitro and hypoglycaemic action in vivo. Br. J. Pharmacol. 149, 870-879. doi: 10.1038/sj.bjp.0706895
204. Romano, S., Coarelli, G., Marcotulli, C., Leonardi, L., Piccolo, F., Spadaro, M., et al. (2015). Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 14, 985-991. doi: 10.1016/S1474-4422(15)00201-X
205. Roussel, J., Labarthe, F., Thireau, J., Ferro, F., Farah, C., Roy, J., et al. (2016). Carnitine deficiency induces a short QT syndrome. Heart Rhythm 13, 165-174. doi: 10.1016/j.hrthm.2015.07.027
206. Ruan, Y., Denegri, M., Liu, N., Bachetti, T., Seregni, M., Morotti, S., et al. (2010). Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3. Circ. Res. 106, 1374-1383. doi: 10.1161/CIRCRESAHA.110.218891
207. Ruan, Y., Liu, N., Bloise, R., Napolitano, C., and Priori, S. G. (2007). Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 116, 1137-1144. doi: 10.1161/CIRCULATIONAHA.107.707877
208. Rubinstein, M., Han, S., Tai, C., Westenbroek, R. E., Hunker, A., Scheuer, T., et al. (2015). Dissecting the phenotypes of Dravet syndrome by gene deletion. Brain 138, 2219-2233. doi: 10.1093/brain/awv142
209. Rusconi, R., Scalmani, P., Cassulini, R. R., Giunti, G., Gambardella, A., Franceschetti, S., et al. (2007). Modulatory proteins can rescue a trafficking defective epileptogenic NaV1.1 Na+ channel mutant. J. Neurosci. 27, 11037-11046. doi: 10.1523/JNEUROSCI.3515-07.2007
210. Russo, R., Caroleo, M. C., Cione, E., Perri, M., Paparo, M. T., and Russo, A. (2015). Dual effect of ziconotide in primary erythromelalgia. Case Rep. Med. 2015, 592170. doi: 10.1155/2015/592170
211. Ryan, D. P., da Silva, M. R., Soong, T. W., Fontaine, B., Donaldson, M. R., Kung, A. W. C., et al. (2010). Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell 140, 88-98. doi: 10.1016/j.cell.2009.12.024
212. Saint-Martin, C., Gauvain, G., Teodorescu, G., Gourfinkel-An, I., Fedirko, E., Weber, Y. G., et al. (2009). Two novel CLCN2 mutations accelerating chloride channel deactivation are associated with idiopathic generalized epilepsy. Hum. Mutat. 30, 397-405. doi: 10.1002/humu.20876
213. Sala-Rabanal, M., Kucheryavykh, L. Y., Skatchkov, S. N., Eaton, M. J., and Nichols, C. G. (2010). Molecular mechanisms of EAST/SeSAME syndrome mutations in Kir4.1 (KCNJ10). J. Biol. Chem. 285, 36040-36048. doi: 10.1074/jbc.M110.163170
214. Sansone, V. A., Burge, J., McDermott, M. P., Smith, P. C., Herr, B., Tawil, R., et al. (2016). Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis. Neurology doi: 10.1212/WNL.0000000000002416 [Epub ahead of print].
215. Schoonjans, A. S., Lagae, L., and Ceulemans, B. (2015). Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome. Ther. Adv. Neurol. Disord. 8, 328-338. doi: 10.1177/1756285615607726
216. Sheets, P. L., Jackson, J. O. II, Waxman, S. G., Dib-Hajj, S. D., and Cummins, T. R. (2007). A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity. J. Physiol. 581, 1019-1031. doi: 10.1113/jphysiol.2006.127027
217. Shulman, M., Harris, J. E., Lubenow, T. R., Nath, H. A., and Ivankovich, A. D. (2000). Comparison of epidural butamben to celiac plexus neurolytic block for the treatment of the pain of pancreatic cancer. Clin. J. Pain 16, 304-309.
218. Shulman, M., Lubenow, T. R., Nath, H. A., Blazek, W., McCarthy, R. J., and Ivankovich, A. D. (1998). Nerve blocks with 5% butamben suspension for the treatment of chronic pain syndromes. Reg. Anesth. Pain. Med. 23, 395-401. doi: 10.1016/S1098-7339(98)90014-1
219. Sicca, F., Imbrici, P., D'Adamo, M. C., Moro, F., Bonatti, F., Brovedani, P., et al. (2011). Autism with seizures and intellectual disability: possible causative role of gain-of-function of the inwardly-rectifying K+ channel Kir4.1. Neurobiol. Dis. 43, 239-247. doi: 10.1016/j.nbd.2011.03.016
220. Simon, D. B., Bindra, R. S., Mansfield, T. A., Nelson-Williams, C., Mendonca, E., Stone, R., et al. (1997). Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat. Genet. 17, 171-178. doi: 10.1038/ng1097-171
221. Simon, D. B., Karet, F. E., Rodriguez-Soriano, J., Hamdan, J. H., DiPietro, A., Trachtman, H., et al. (1996). Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. Nat. Genet. 14, 152-156. doi: 10.1038/ng1096-152
222. Skalova, S., Svadlakova, T., Shaikh Qureshi, W. M., Dev, K., and Mokry, J. (2015). Induced pluripotent stem cells and their use in cardiac and neural regenerative medicine. Int. J. Mol. Sci. 16, 4043-4067. doi: 10.3390/ijms16024043
223. Smart, S. L., Lopantsev, V., Zhang, C. L., Robbins, C. A., Wang, H., Chiu, S. Y., et al. (1998). Deletion of the K(V)1.1 potassium channel causes epilepsy in mice. Neuron 20, 809-819. doi: 10.1016/S0896-6273(00)81018-1
224. Snowball, A., and Schorge, S. (2015). Changing channels in pain and epilepsy: exploiting ion channel gene therapy for disorders of neuronal hyperexcitability. FEBS Lett. 589, 1620-1634. doi: 10.1016/j.febslet.2015.05.004
225. Soares-da-Silva, P., Pires, N., Bonifácio, M. J., Loureiro, A. I., Palma, N., and Wright, L. C. (2015). Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action. Pharmacol. Res. Perspect. 3:e00124. doi: 10.1002/prp2.124
226. Sobacchi, C., Schulz, A., Coxon, F. P., Villa, A., and Helfrich, M. H. (2013). Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat. Rev. Endocrinol. 9, 522-536. doi: 10.1038/nrendo.2013.137
227. Sokolov, S., Scheuer, T., and Catterall, W. A. (2007). Gating pore current in an inherited ion channelopathy. Nature 446, 76-78. doi: 10.1038/nature05598
228. Sokolov, S., Scheuer, T., and Catterall, W. A. (2010). Ion permeation and block of the gating pore in the voltage sensor of NaV1.4 channels with hypokalemic periodic paralysis. J. Gen. Physiol. 136, 225-236. doi: 10.1085/jgp.201010414
229. Soldovieri, M. V., Miceli, F., and Taglialatela, M. (2011). Driving with no brakes: molecular pathophysiology of Kv7 potassium channels. Physiology (Bethesda) 26, 365-376. doi: 10.1152/physiol.00009.2011
230. Spears, D. A., and Gollob, M. H. (2015). Genetics of inherited primary arrhythmia disorders. Appl. Clin. Genet. 8, 215-233. doi: 10.2147/TACG.S55762
231. Spillane, J., Kullmann, D. M., and Hanna, M. G. (2016). Genetic neurological channelopathies: molecular genetics and clinical phenotypes. J. Neurol. Neurosurg. Psychiatry 87, 37-48. doi: 10.1136/jnnp-2015-311233
232. Splawski, I., Timothy, K. W., Sharpe, L. M., Decher, N., Kumar, P., Bloise, R., et al. (2004). Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119, 19-31. doi: 10.1016/j.cell.2004.09.011
233. Statland, J. M., Bundy, B. N., Wang, Y., Rayan, D. R., Trivedi, J. R., Sansone, V. A., et al. (2012). Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA 308, 1357-1365. doi: 10.1001/jama.2012.12607
234. Steinke, K. V., Gorinski, N., Wojciechowski, D., Todorov, V., Guseva, D., Ponimaskin, E., et al. (2015). Human CLC-K channels require palmitoylation of their accessory subunit barttin to be functional. J. Biol. Chem. 290, 17390-17400. doi: 10.1074/jbc.M114.631705
235. Sternberg, D., Maisonobe, T., Jurkat-Rott, K., Nicole, S., Launay, E., Chauveau, D., et al. (2001). Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. Brain 124, 1091-1099. doi: 10.1093/brain/124.6.1091
236. Strupp, M., Zwergal, A., Feil, K., Bremova, T., and Brandt, T. (2015). Pharmacotherapy of vestibular and cerebellar disorders and downbeat nystagmus: translational and back-translational research. Ann. N. Y. Acad. Sci. 1343, 27-36. doi: 10.1111/nyas.12774
237. Struyk, A. F., and Cannon, S. C. (2007). A Na+ channel mutation linked to hypokalemic periodic paralysis exposes a proton-selective gating pore. J. Gen. Physiol. 130, 11-20. doi: 10.1085/jgp.200709755
238. Suetterlin, K. J., Bugiardini, E., Kaski, J. P., Morrow, J. M., Matthews, E., Hanna, M. G., et al. (2015). Long-term safety and efficacy of mexiletine for patients with skeletal muscle channelopathies. JAMA Neurol. 72, 1531-1533. doi: 10.1001/jamaneurol.2015.2338
239. Swaggart, K. A., and McNally, E. M. (2014). Modifiers of heart and muscle function: where genetics meets physiology. Exp. Physiol. 99, 621-626. doi: 10.1113/expphysiol.2013.075887
240. Syrbe, S., Hedrich, U. B., Riesch, E., Djémié, T., Müller, S., Møller, R. S., et al. (2015). De novo loss-or gain-of-function mutations in KCNA2 cause epileptic encephalopathy. Nat. Genet. 47, 393-399. doi: 10.1038/ng.3239
241. Takahashi, M. P., and Cannon, S. C. (2001). Mexiletine block of disease-associated mutations in S6 segments of the human skeletal muscle Na+ channel. J. Physiol. 537, 701-714. doi: 10.1113/jphysiol.2001.012541
242. Talon, S., De Luca, A., De Bellis, M., Desaphy, J. F., Lentini, G., Scilimati, A., et al. (2001). Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the antimyotonic activity in vivo. Br. J. Pharmacol. 134, 1523-1531. doi: 10.1038/sj.bjp.0704366
243. Tang, B., Dutt, K., Papale, L., Rusconi, R., Shankar, A., Hunter, J., et al. (2009). A BAC transgenic mouse model reveals neuron subtype-specific effects of a Generalized Epilepsy with Febrile Seizures Plus (GEFS+) mutation. Neurobiol. Dis. 35, 91-102. doi: 10.1016/j.nbd.2009.04.007
244. Tang, Q. Y., Zhang, F. F., Xu, J., Wang, R., Chen, J., Logothetis, D. E., et al. (2016). Epilepsy-related slack channel mutants lead to channel over-activity by two different mechanisms. Cell Rep. 14, 129-139. doi: 10.1016/j.celrep.2015.12.019
245. Tawil, R., Ptacek, L. J., Pavlakis, S. G., DeVivo, D. C., Penn, A. S., Ozdemir, C., et al. (1994). Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann. Neurol. 35, 326-330. doi: 10.1002/ana.410350313
246. Theile, J. W., and Cummins, T. R. (2011). Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes. Front. Pharmacol. 2:54. doi: 10.3389/fphar.2011.00054
247. Thériault, O., Poulin, H., Sculptoreanu, A., de Groat, W. C., O'Leary, M. E., and Chahine, M. (2014). Modulation of peripheral Na+ channels and neuronal firing by n-butyl-p-aminobenzoate. Eur. J. Pharmacol. 727, 158-166. doi: 10.1016/j.ejphar.2014.01.036
248. Tikhonov, D. B., and Zhorov, B. S. (2012). Architecture and pore block of eukaryotic voltage-gated sodium channels in view of NavAb bacterial sodium channel structure. Mol. Pharmacol. 82, 97-104. doi: 10.1124/mol.112.078212
249. Tottene, A., Conti, R., Fabbro, A., Vecchia, D., Shapovalova, M., Santello, M., et al. (2009). Enhanced excitatory transmission at cortical synapses as the basis for facilitated spreading depression in Ca(v)2.1 knockin migraine mice. Neuron 61, 762-773. doi: 10.1016/j.neuron.2009.01.027
250. Tricarico, D., and Camerino, D. C. (2011). Recent advances in the pathogenesis and drug action in periodic paralyses and related channelopathies. Front Pharmacol. 2:8. doi: 10.3389/fphar.2011.00008
251. Tricarico, D., Mele, A., Calzolaro, S., Cannone, G., Camerino, G. M., Dinardo, M. M., et al. (2013). Emerging role of calcium-activated potassium channel in the regulation of cell viability following potassium ions challenge in HEK293 cells and pharmacological modulation. PLoS ONE 8:e69551. doi: 10.1371/journal.pone.0069551
252. Tricarico, D., Mele, A., Camerino, G. M., Laghezza, A., Carbonara, G., Fracchiolla, G., et al. (2008a). Molecular determinants for the activating/blocking actions of the 2H-1, 4-benzoxazine derivatives, a class of potassium channel modulators targeting the skeletal muscle KATP channels. Mol. Pharmacol. 74, 50-58. doi: 10.1124/mol.108.046615
253. Tricarico, D., Mele, A., and Conte Camerino, D. (2006). Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+-activated-K+ channels. Neuromuscul. Disord. 16, 39-45. doi: 10.1016/j.nmd.2005.10.005
254. Tricarico, D., Mele, A., Liss, B., Ashcroft, F. M., Lundquist, A. L., Desai, R. R., et al. (2008b). Reduced expression of Kir6.2/SUR2A subunits explains KATP deficiency in K+-depleted rats. Neuromuscul. Disord. 18, 74-80. doi: 10.1016/j.nmd.2007.07.009
255. Tricarico, D., Montanari, L., and Conte Camerino, D. (2003). Involvement of 3Na+/2K+ ATP-ase and Pi-3 kinase in the response of skeletal muscle ATP-sensitive K+ channels to insulin. Neuromuscul. Disord. 13, 712-719. doi: 10.1016/S0960-8966(03)00095-6
256. Tricarico, D., Rolland, J. F., Cannone, G., Mele, A., Cippone, V., Laghezza, A., et al. (2012). Structural nucleotide analogs are potent activators/inhibitors of pancreatic β cell KATP channels: an emerging mechanism supporting their use as antidiabetic drugs. J. Pharmacol. Exp. Ther. 340, 266-276. doi: 10.1124/jpet.111.185835
257. Trudell, R. G., Kaiser, K. K., and Griggs, R. C. (1987). Acetazolamide-responsive myotonia congenita. Neurology 37, 488-491. doi: 10.1212/WNL.37.3.488
258. Unwin, R. J., and Capasso, G. (2006). Bartter's and Gitelman's syndromes: their relationship to the actions of loop and thiazide diuretics. Curr. Opin. Pharmacol. 6, 208-213. doi: 10.1016/j.coph.2006.01.002
259. van der Knaap, M. S., and Scheper, G. C. (2011). "Megalencephalic Leukoencephalopathy with Subcortical Cysts, " in GeneReviews[Internet], eds R. A. Pagon, M. P. Adam, H. H. Ardinger, S. E. Wallace, A. Amemiya, L. J. H. Bean, et al. (Seattlem, WA: University of Washington).
260. Vanoye, C. G., Gurnett, C. A., Holland, K. D., George, A. L. Jr., and Kearney, J. A. (2013). Novel SCN3A variants associated with focal epilepsy in children. Neurobiol. Dis. 62, 313-322. doi: 10.1016/j.nbd.2013.10.015
261. Verkman, A. S., and Galietta, L. J. (2009). Chloride channels as drug targets. Nat. Rev. Drug Discov. 8, 153-171. doi: 10.1038/nrd2780
262. Wagnon, J. L., and Meisler, M. H. (2015). Recurrent and non-recurrent mutations of SCN8A in epileptic encephalopathy. Front. Neurol. 6:104. doi: 10.3389/fneur.2015.00104
263. Walker, L. E., Mirza, N., Yip, V. L., Marson, A. G., and Pirmohamed, M. (2015). Personalized medicine approaches in epilepsy. J. Intern. Med. 277, 218-234. doi: 10.1111/joim.12322
264. Walter, J. T., Alviña, K., Womack, M. D., Chevez, C., and Khodakhah, K. (2006). Decreases in the precision of Purkinje cell pacemaking cause cerebellar dysfunction and ataxia. Nat. Neurosci. 9, 389-397. doi: 10.1038/nn1648
265. Wang, G., Bochorishvili, G., Chen, Y., Salvati, K. A., Zhang, P., Dubel, S. J., et al. (2015). CaV3.2 calcium channels control NMDA receptor-mediated transmission: a new mechanism for absence epilepsy. Genes Dev. 29, 1535-1551. doi: 10.1101/gad.260869.115
266. Wang, Q., Curran, M. E., Splawski, I., Burn, T. C., Millholland, J. M., VanRaay, T. J., et al. (1996). Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat. Genet. 12, 17-23. doi: 10.1038/ng0196-17
267. Wang, S. S., Devuyst, O., Courtoy, P. J., Wang, X. T., Wang, H., Wang, Y., et al. (2000). Mice lacking renal chloride channel, CLC-5, are a model for Dent's disease, a nephrolithiasis disorder associated with defective receptor-mediated endocytosis. Hum. Mol. Genet. 9, 2937-2945. doi: 10.1093/hmg/9.20.2937
268. Watson, L. M., Wong, M. M., and Becker, E. B. (2015). Induced pluripotent stem cell technology for modelling and therapy of cerebellar ataxia. Open Biol. 5:150056. doi: 10.1098/rsob.150056
269. Waxman, S. G., Merkies, I. S., Gerrits, M. M., Dib-Hajj, S. D., Lauria, G., Cox, J. J., et al. (2014). Sodium channel genes in pain-related disorders: phenotype-genotype associations and recommendations for clinical use. Lancet Neurol. 13, 1152-1160. doi: 10.1016/S1474-4422(14)70150-4
270. Weinert, S., Jabs, S., Hohensee, S., Chan, W. L., Kornak, U., and Jentsch, T. J. (2014). Transport activity and presence of ClC-7/Ostm1 complex account for different cellular functions. EMBO Rep 15, 784-791. doi: 10.15252/embr.201438553
271. Welling, P. A., and Ho, K. (2009). A comprehensive guide to the ROMK potassium channel: form and function in health and disease. Am. J. Physiol. Renal. Physiol. 297, F849-F863. doi: 10.1152/ajprenal.00181.2009
272. Welters, A., Lerch, C., Kummer, S., Marquard, J., Salgin, B., Mayatepek, E., et al. (2015). Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers. Orphanet. J. Rare Dis. 10:150. doi: 10.1186/s13023-015-0367-x
273. Wheeler, A., Wang, C., Yang, K., Fang, K., Davis, K., Styer, A. M., et al. (2008). Coassembly of different sulfonylurea receptor subtypes extends the phenotypic diversity of ATP-sensitive potassium (KATP) channels. Mol. Pharmacol. 74, 1333-1344. doi: 10.1124/mol.108.048355
274. Wu, F., Mi, W., and Cannon, S. C. (2013). Beneficial effects of bumetanide in a CaV1.1-R528H mouse model of hypokalaemic periodic paralysis. Brain 136(Pt 12), 3766-3774. doi: 10.1093/brain/awt280
275. Wuttke, T. V., Jurkat-Rott, K., Paulus, W., Garncarek, M., Lehmann-Horn, F., and Lerche, H. (2007). Peripheral nerve hyperexcitability due to dominant-negative KCNQ2 mutations. Neurology 9, 2045-2053. doi: 10.1212/01.wnl.0000275523.95103.36
276. Yamamoto, S., Kita, S., Iyoda, T., Yamada, T., and Iwamoto, T. (2011). New molecular mechanisms for cardiovascular disease: cardiac hypertrophy and cell-volume regulation. J. Pharmacol. Sci. 116, 343-349. doi: 10.1254/jphs.10R31FM
277. Yang, Y., Dib-Hajj, S. D., Zhang, J., Zhang, Y., Tyrrell, L., Estacion, M., et al. (2012). Structural modelling and mutant cycle analysis predict pharmacoresponsiveness of a Nav1.7 mutant channel. Nat. Commun. 3:1186. doi: 10.1038/ncomms2184
278. Yang, Y., Wang, Y., Li, S., Xu, Z., Li, H., Ma, L., et al. (2004). Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J. Med. Genet. 41, 171-174. doi: 10.1136/jmg.2003.012153
279. Yazawa, M., and Dolmetsch, R. E. (2013). Modeling Timothy syndrome with iPS cells. J. Cardiovasc. Transl. Res. 6, 1-9. doi: 10.1007/s12265-012-9444-x
280. Yuan, J., Matsuura, E., Higuchi, Y., Hashiguchi, A., Nakamura, T., Nozuma, S., et al. (2013). Hereditary sensory and autonomic neuropathy type IID caused by an SCN9A mutation. Neurology 80, 1641-1649. doi: 10.1212/WNL.0b013e3182904fdd
281. Zaharieva, I. T., Thor, M. G., Oates, E. C., van Karnebeek, C., Hendson, G., Blom, E., et al. (2015). Loss-of-function mutations in SCN4A cause severe foetal hypokinesia or 'classical' congenital myopathy. Brain doi: 10.1093/brain/awv352 [Epub ahead of print].
282. Zamponi, G. W., Striessnig, J., Koschak, A., and Dolphin, A. C. (2015). The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol. Rev. 67, 821-870. doi: 10.1124/pr.114.009654
283. Zhang, X. Y., Wen, J., Yang, W., Wang, C., Gao, L., Zheng, L. H., et al. (2013). Gain-of-function mutations in SCN11A cause familial episodic pain. Am. J. Hum. Genet. 93, 957-966. doi: 10.1016/j.ajhg.2013.09.016
284. Zhao, Q., Wei, Q., He, A., Jia, R., and Xiao, Y. (2009). CLC-7: a potential therapeutic target for the treatment of osteoporosis and neurodegeneration. Biochem. Biophys. Res. Commun. 384, 277-279. doi: 10.1016/j.bbrc.2009.04.088
285. Zou, B. (2015). Ion channel profiling to advance drug discovery and development. Drug Discov. Today Technol. 18, 18-23. doi: 10.1016/j.ddtec.2015.10.003